The MondoA-dependent TXNIP/GDF15 axis predicts oxaliplatin response in colorectal adenocarcinomas.
Colorectal Cancer
Functional Biomarker
GDF15
Oxaliplatin
TXNIP
Journal
EMBO molecular medicine
ISSN: 1757-4684
Titre abrégé: EMBO Mol Med
Pays: Germany
ID NLM: 101487380
Informations de publication
Date de publication:
05 Aug 2024
05 Aug 2024
Historique:
received:
29
01
2024
accepted:
03
07
2024
revised:
21
06
2024
medline:
6
8
2024
pubmed:
6
8
2024
entrez:
5
8
2024
Statut:
aheadofprint
Résumé
Chemotherapy, the standard of care treatment for cancer patients with advanced disease, has been increasingly recognized to activate host immune responses to produce durable outcomes. Here, in colorectal adenocarcinoma (CRC) we identify oxaliplatin-induced Thioredoxin-Interacting Protein (TXNIP), a MondoA-dependent tumor suppressor gene, as a negative regulator of Growth/Differentiation Factor 15 (GDF15). GDF15 is a negative prognostic factor in CRC and promotes the differentiation of regulatory T cells (Tregs), which inhibit CD8 T-cell activation. Intriguingly, multiple models including patient-derived tumor organoids demonstrate that the loss of TXNIP and GDF15 responsiveness to oxaliplatin is associated with advanced disease or chemotherapeutic resistance, with transcriptomic or proteomic GDF15/TXNIP ratios showing potential as a prognostic biomarker. These findings illustrate a potentially common pathway where chemotherapy-induced epithelial oxidative stress drives local immune remodeling for patient benefit, with disruption of this pathway seen in refractory or advanced cases.
Identifiants
pubmed: 39103698
doi: 10.1038/s44321-024-00105-2
pii: 10.1038/s44321-024-00105-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : China Scholarship Council (CSC)
ID : 201806010012
Organisme : China Scholarship Council (CSC)
ID : 202006940028
Organisme : China Scholarship Council (CSC)
ID : 202306010087
Organisme : UKRI | Medical Research Council (MRC)
ID : MR/R000026/1
Organisme : Cancer Research UK (CRUK)
ID : C7675/A29313
Organisme : Cancer Research UK (CRUK)
ID : C7675/A29313
Organisme : Cancer Research UK (CRUK)
ID : 176885
Organisme : Cancer Research UK (CRUK)
ID : CTRQQR-2021\100004
Organisme : Cancer Research UK (CRUK)
ID : 202306010087
Organisme : Cancer Research UK (CRUK)
ID : C1519/A27375
Organisme : Breast Cancer Now (BCN)
ID : KCL-Q2-Y5
Informations de copyright
© 2024. The Author(s).
Références
Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE (2001) Cyclooxygenase inhibitors regulate the expression of a TGF-β superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 59(4):901–908. https://doi.org/10.1124/MOL.59.4.901
doi: 10.1124/MOL.59.4.901
pubmed: 11259636
Bauskin AR, Brown DA, Kuffner T, Johnen H, Lou XW, Hunter M, Breit SN (2006) Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res 66(10):4983–4986. https://doi.org/10.1158/0008-5472.CAN-05-4067
doi: 10.1158/0008-5472.CAN-05-4067
pubmed: 16707416
Betts G, Jones E, Junaid S, El-Shanawany T, Scurr M, Mizen P, Kumar M, Jones S, Rees B, Williams G et al (2012) Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut 61(8):1163–1171. https://doi.org/10.1136/GUTJNL-2011-300970
doi: 10.1136/GUTJNL-2011-300970
pubmed: 22207629
Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K et al (1997) MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily. Proc Natl Acad Sci USA 94:11514–11519
doi: 10.1073/pnas.94.21.11514
pubmed: 9326641
pmcid: 23523
Boyle GM, Pedley J, Martyn AC, Banducci KJ, Strutton GM, Brown DA, Breit SN, Parsons PG (2009) Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity. J Investig Dermatol 129(2):383–391. https://doi.org/10.1038/JID.2008.270
doi: 10.1038/JID.2008.270
pubmed: 18754039
BR W, DE A (2015) Interactions between Myc and MondoA transcription factors in metabolism and tumourigenesis. Br J Cancer 113(11):1529–1533. https://doi.org/10.1038/BJC.2015.360
doi: 10.1038/BJC.2015.360
Brown DA, Ward RL, Buckhaults P, Liu T, Romans KE, Hawkins NJ, Bauskin AR, Kinzler KW, Vogelstein B, Breit SN (2003) MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res 9(7):2642–2650
pubmed: 12855642
Brown DA, Stephan C, Ward RL, Law M, Hunter M, Bauskin AR, Amin J, Jung K, Diamandis EP, Hampton GM et al (2006) Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Clin Cancer Res 12(1):89–96. https://doi.org/10.1158/1078-0432.CCR-05-1331
doi: 10.1158/1078-0432.CCR-05-1331
pubmed: 16397029
Deng J, Pan T, Liu Z, McCarthy C, Vicencio JM, Cao L, Alfano G, Suwaidan AA, Yin M, Beatson R et al (2023) The role of TXNIP in cancer: a fine balance between redox, metabolic, and immunological tumor control. Br J Cancer 129:1877–1892. https://doi.org/10.1038/s41416-023-02442-4
Di Y, Jiang Y, Shen X, Liu J, Gao Y, Cai H, Sun X, Ning D, Liu B, Lei J et al (2021) Downregulation of MiR-135b-5p suppresses progression of esophageal cancer and contributes to the effect of cisplatin. Front Oncol 11:2363. https://doi.org/10.3389/FONC.2021.679348/BIBTEX
doi: 10.3389/FONC.2021.679348/BIBTEX
Emmerson PJ, Wang F, Du Y, Liu Q, Pickard RT, Gonciarz MD, Coskun T, Hamang MJ, Sindelar DK, Ballman KK et al (2017) The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL. Nat Med 23(10):1215–1219. https://doi.org/10.1038/nm.4393
doi: 10.1038/nm.4393
pubmed: 28846098
Fekete JT, Győrffy B (2023) New transcriptomic biomarkers of 5-fluorouracil resistance. Int J Mol Sci 24(2):1–12. https://doi.org/10.3390/ijms24021508
doi: 10.3390/ijms24021508
Gadiyar V, Lahey KC, Calianese D, Devoe C, Mehta D, Bono K, Desind S, Davra V, Birge RB (2020) Cell death in the tumor microenvironment: implications for cancer immunotherapy. Cells 9(10):2207. https://doi.org/10.3390/CELLS9102207
Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW et al (2018) Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death. Cell Death Differ 25(3):486–541. https://doi.org/10.1038/s41418-017-0012-4
doi: 10.1038/s41418-017-0012-4
pubmed: 29362479
pmcid: 5864239
Gao Q, Wang S, Chen X, Cheng S, Zhang Z, Li F, Huang L, Yang Y, Zhou B, Yue D et al (2019) Cancer-cell-secreted CXCL11 promoted CD8+ T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC. J Immunother Cancer 7(1):42. https://doi.org/10.1186/S40425-019-0511-6
doi: 10.1186/S40425-019-0511-6
pubmed: 30744691
pmcid: 6371476
Gao Y, Xu Y, Zhao S, Qian L, Song T, Zheng J, Zhang J, Chen B (2021) Growth differentiation factor-15 promotes immune escape of ovarian cancer via targeting CD44 in dendritic cells. Exp Cell Res 402(1):112522. https://doi.org/10.1016/J.YEXCR.2021.112522
doi: 10.1016/J.YEXCR.2021.112522
pubmed: 33771482
Gebremeskel S, Lobert L, Tanner K, Walker B, Oliphant T, Clarke LE, Dellaire G, Johnston B (2017) Natural killer T-cell immunotherapy in combination with chemotherapy-induced immunogenic cell death targets metastatic breast cancer. Cancer Immunol Res 5(12):1086–1097. https://doi.org/10.1158/2326-6066
doi: 10.1158/2326-6066
pubmed: 29054890
Guo X, Huang M, Zhang H, Chen Q, Hu Y, Meng Y, Wu C, Tu C, Liu Y, Li A et al (2022) A Pan-cancer analysis of thioredoxin-interacting protein as an immunological and prognostic biomarker. Cancer Cell Int 22(1):1–16. https://doi.org/10.1186/s12935-022-02639-2
doi: 10.1186/s12935-022-02639-2
Hess GP, Wang PF, Quach D, Barber B, Zhao Z (2010) “Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US Medical Oncology Practice. J Oncol Pract 6(6):301–307. https://doi.org/10.1200/JOP.2010.000072
doi: 10.1200/JOP.2010.000072
pubmed: 21358960
pmcid: 2988664
Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, Gameiro SR (2013) Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer J Int Du Cancer 133(3):624. https://doi.org/10.1002/IJC.28070
doi: 10.1002/IJC.28070
Hsu JY, Crawley S, Chen M, Ayupova DA, Lindhout DA, Higbee J, Kutach A, Joo W, Gao Z, Fu D et al (2017) Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. Nature 550(7675):255–259. https://doi.org/10.1038/nature24042
doi: 10.1038/nature24042
pubmed: 28953886
Jensen C, Teng Y (2020) Is it time to start transitioning from 2D to 3D cell culture? Front Mol Biosci 7:33. https://doi.org/10.3389/FMOLB.2020.00033/BIBTEX
doi: 10.3389/FMOLB.2020.00033/BIBTEX
pubmed: 32211418
pmcid: 7067892
Jeon J-H, Lee K-N, Hwang CY, Kwon K-S, You K-H, Choi I (2005) Tumor suppressor VDUP1 increases P27kip1 stability by inhibiting JAB1. Cancer Res 65(11):4485–4489. https://doi.org/10.1158/0008-5472.CAN-04-2271
doi: 10.1158/0008-5472.CAN-04-2271
pubmed: 15930262
Jiao D, Huan Y, Zheng J, Wei M, Zheng G, Han D, Wu J, Xi W, Wei F, Yang A-G et al (2019) UHRF1 promotes renal cell carcinoma progression through epigenetic regulation of TXNIP. Oncogene 38(28):5686–5699
Joanito I, Wirapati P, Zhao N, Nawaz Z, Yeo G, Lee F, Eng CLP, Macalinao DC, Kahraman M, Srinivasan H et al (2022) Single-cell and Bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancer. Nat Genet 18:1–13
Jobin G, Rodriguez-Suarez R, Betito K (2017) Association between natural killer cell activity and colorectal cancer in high-risk subjects undergoing colonoscopy. Gastroenterology 153(4):980–987. https://doi.org/10.1053/J.GASTRO.2017.06.009
doi: 10.1053/J.GASTRO.2017.06.009
pubmed: 28625834
Junn E, Han SH, Im JY, Yang Y, Cho EW, Um HD, Kim DK, Lee KW, Han PL, Rhee SG et al (2000) Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J Immunol 164(12):6287–6295. https://doi.org/10.4049/JIMMUNOL.164.12.6287
doi: 10.4049/JIMMUNOL.164.12.6287
pubmed: 10843682
Kalafati L, Kourtzelis I, Schulte-Schrepping J, Li X, Hatzioannou A, Grinenko T, Hagag E, Sinha A, Has C, Dietz S et al (2020) Innate immune training of granulopoiesis promotes anti-tumor activity. Cell 183(3):771–785.e12
doi: 10.1016/j.cell.2020.09.058
pubmed: 33125892
pmcid: 7599076
Kim, JM, JP Kosak, JK Kim, G Kissling, DR Germolec, DC Zeldin, JA Bradbury, SJ Baek, TE Eling (2013) NAG-1/GDF15 transgenic mouse has less white adipose tissue and a reduced inflammatory response. Mediators Inflam. https://doi.org/10.1155/2013/641851
Klein Geltink RI, O’Sullivan D, Corrado M, Bremser A, Buck MD, Buescher JM, Firat E, Zhu X, Niedermann G, Caputa G et al (2017) Mitochondrial priming by CD28. Cell 171(2):385–397.e11. https://doi.org/10.1016/J.CELL.2017.08.018
doi: 10.1016/J.CELL.2017.08.018
pubmed: 28919076
pmcid: 5637396
Kleinertz H, Hepner-Schefczyk M, Ehnert S, Claus M, Halbgebauer R, Boller L, Huber-Lang M, Cinelli P, Kirschning C, Flohé S et al (2019) Circulating growth/differentiation factor 15 is associated with human CD56bright natural killer cell dysfunction and nosocomial infection in severe systemic inflammation. EBioMedicine 43:380–391
doi: 10.1016/j.ebiom.2019.04.018
pubmed: 30992245
pmcid: 6557805
Kroemer G, Galluzzi L, Kepp O, Zitvogel L (2013) Immunogenic cell death in cancer therapy. Annu Rev Immunol 31:51–72. https://doi.org/10.1146/ANNUREV-IMMUNOL-032712-100008
Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P (2012) Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 12(12):860–875
Kuljaca S, Liu T, Dwarte T, Kavallaris M, Haber M, Norris MD, Martin-Caballero J, Marshall GM (2009) The cyclin-dependent kinase inhibitor, P21 WAF1, promotes angiogenesis by repressing gene transcription of thioredoxin-binding protein 2 in cancer cells. Carcinogenesis 30(11):1865–1871. https://doi.org/10.1093/CARCIN/BGP225
doi: 10.1093/CARCIN/BGP225
pubmed: 19773351
Lim TY, Wilde BR, Thomas ML, Murphy KE, Vahrenkamp JM, Conway ME, Varley KE, Gertz J, Ayer DE (2023) TXNIP loss expands Myc-dependent transcriptional programs by increasing Myc genomic binding. PLoS Biol 21(3):1–29. https://doi.org/10.1371/journal.pbio.3001778
doi: 10.1371/journal.pbio.3001778
Lin S, Ewen-Campen B, Ni X, Housden BE, Perrimon N (2015) In vivo transcriptional activation using CRISPR/Cas9 in Drosophila. Genetics 201(2):433–442. https://doi.org/10.1534/GENETICS.115.181065
doi: 10.1534/GENETICS.115.181065
pubmed: 26245833
pmcid: 4596659
Lu J, Holmgren A (2014) The thioredoxin antioxidant system. Free Radic Biol Med 66:75–87. https://doi.org/10.1016/J.FREERADBIOMED.2013.07.036
doi: 10.1016/J.FREERADBIOMED.2013.07.036
pubmed: 23899494
Lu Y, Li Y, Liu Q, Tian N, Du P, Zhu F, Han Y, Liu X, Liu X, Peng X et al (2021) MondoA–thioredoxin-interacting protein axis maintains regulatory T-cell identity and function in colorectal cancer microenvironment. Gastroenterology 161(2):575–591.e16
doi: 10.1053/j.gastro.2021.04.041
pubmed: 33901495
Masutani H (2022) Thioredoxin-interacting protein in cancer and diabetes. Antioxidants Redox Signal 36(13–15):1001–1022. https://doi.org/10.1089/ARS.2021.0038
Morrison JA, Pike LA, Sams SB, Sharma V, Zhou Q, Severson JJ, Choon Tan A, Wood WM, Haugen BR (2014) Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer. Mol Cancer 13(1):1–13. https://doi.org/10.1186/1476-4598-13-62/FIGURES/5
doi: 10.1186/1476-4598-13-62/FIGURES/5
Mullican SE, Lin-Schmidt X, Chin CN, Chavez JA, Furman JL, Armstrong AA, Beck SC, South VJ, Dinh TQ, Cash-Mason TD et al (2017) GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat Med 23(10):1150–57
Muri J, Thut H, Kopf M (2021) The thioredoxin-1 inhibitor txnip restrains effector T-cell and germinal center B-cell expansion. Eur J Immunol 51(1):115–124. https://doi.org/10.1002/EJI.202048851
doi: 10.1002/EJI.202048851
pubmed: 32902872
Nishiyama A, Matsui M, Iwata S, Hirota K, Masutani H, Nakamura H, Takagi Y, Sono H, Gon Y, Yodoi J (1999) Identification of thioredoxin-binding protein-2/vitamin D3 up-regulated protein 1 as a negative regulator of thioredoxin function and expression *. J Biol Chem 274(31):21645–21650. https://doi.org/10.1074/JBC.274.31.21645
doi: 10.1074/JBC.274.31.21645
pubmed: 10419473
Nishizawa K, Nishiyama H, Matsui Y, Kobayashi T, Saito R, Kotani H, Masutani H, Oishi S, Toda Y, Fujii N et al (2011) Thioredoxin-interacting protein suppresses bladder carcinogenesis. Carcinogenesis 32(10):1459–1466. https://doi.org/10.1093/CARCIN/BGR137
doi: 10.1093/CARCIN/BGR137
pubmed: 21771725
Ogata FT, Batista WL, Sartori A, Gesteira TF, Masutani H, Arai RJ, Yodoi J, Stern A, Monteiro HP (2013) Nitrosative/oxidative stress conditions regulate thioredoxin-interacting protein (TXNIP) expression and thioredoxin-1 (TRX-1) nuclear localization. PLoS ONE 8(12):e84588. https://doi.org/10.1371/JOURNAL.PONE.0084588
Olsen OE, Skjærvik A, Størdal BF, Sundan A, Holien T (2017) TGF-β contamination of purified recombinant GDF15. PLoS ONE 12(11):e0187349. https://doi.org/10.1371/JOURNAL.PONE.0187349
doi: 10.1371/JOURNAL.PONE.0187349
pubmed: 29161287
pmcid: 5697882
Opzoomer JW, Sosnowska D, Anstee JE, Spicer JF, Arnold JN (2019) Cytotoxic chemotherapy as an immune stimulus: a molecular perspective on turning up the immunological heat on cancer. Front Immunol 10(JULY):1654. https://doi.org/10.3389/FIMMU.2019.01654/BIBTEX
doi: 10.3389/FIMMU.2019.01654/BIBTEX
pubmed: 31379850
pmcid: 6652267
Pan T, Zhou D, Shi Z, Qiu Y, Zhou G, Liu J, Yang Q, Cao L, Zhang J (2020) Centromere protein U (CENPU) enhances angiogenesis in triple-negative breast cancer by inhibiting ubiquitin-proteasomal degradation of COX-2. Cancer Lett 482:102–11
Parra ER, Villalobos P, Behrens C, Jiang M, Pataer A, Swisher SG, William WN, Zhang J, Lee J, Cascone T et al (2018) Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J Immunother Cancer 6(1):1–11. https://doi.org/10.1186/S40425-018-0368-0
Perillo B, Di Donato M, Pezone A, Di Zazzo E, Giovannelli P, Galasso G, Castoria G, Migliaccio A (2020) ROS in cancer therapy: the bright side of the moon. Exp Mol Med 52(2):192–203
Peterson CW, Stoltzman CA, Sighinolfi MP, Han K-S, Ayer DE (2010) Glucose controls nuclear accumulation, promoter binding, and transcriptional activity of the MondoA-Mlx heterodimer. Mol Cell Biol 30(12):2887–2895. https://doi.org/10.1128/mcb.01613-09
Richards P, Rachdi L, Oshima M, Marchetti P, Bugliani M, Armanet M, Postic C, Guilmeau S, Scharfmann R (2018) MondoA is an essential glucose-responsive transcription factor in human pancreatic β-cells. Diabetes 67(3):461–472. https://doi.org/10.2337/DB17-0595
doi: 10.2337/DB17-0595
pubmed: 29282201
Rochette L, Zeller M, Cottin Y, Vergely C (2020) Insights into mechanisms of GDF15 and receptor GFRAL: therapeutic targets. Trends Endocrinol Metab 31(12):939–951. https://doi.org/10.1016/J.TEM.2020.10.004
doi: 10.1016/J.TEM.2020.10.004
pubmed: 33172749
Roth P, Junker M, Tritschler I, Mittelbronn M, Dombrowski Y, Breit SN, Tabatabai G, Wick W, Weller M, Wischhusen J (2010) GDF-15 contributes to proliferation and immune escape of malignant gliomas. Clin Cancer Res 16(15):3851–3859
doi: 10.1158/1078-0432.CCR-10-0705
pubmed: 20534737
Rottenberg S, Disler C, Perego P (2020) The rediscovery of platinum-based cancer therapy. Nat Rev Cancer 21(1):37–50
Santoro V, Jia R, Thompson H, Nijhuis A, Jeffery R, Kiakos K, Silver AR, Hartley JA, Hochhauser D (2016) Role of reactive oxygen species in the abrogation of oxaliplatin activity by cetuximab in colorectal cancer. JNCI J Natl Cancer Inst 108(6):394. https://doi.org/10.1093/JNCI/DJV394
doi: 10.1093/JNCI/DJV394
Sato T, Stange DE, Ferrante M, Vries RGJ, Van Es JH, Van Den Brink S, Van Houdt WJ, Pronk A, Van Gorp J, Siersema PD et al (2011) Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology 141(5):1762–1772. https://doi.org/10.1053/j.gastro.2011.07.050
doi: 10.1053/j.gastro.2011.07.050
pubmed: 21889923
Scharping NE, Rivadeneira DB, Menk AV, Vignali PDA, Ford BR, Rittenhouse NL, Peralta R, Wang Y, Wang Y, DePeaux K et al (2021) Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol 22(2):205–215. https://doi.org/10.1038/S41590-020-00834-9
doi: 10.1038/S41590-020-00834-9
pubmed: 33398183
pmcid: 7971090
Schilsky RL (2018) A new IDEA in adjuvant chemotherapy for colon cancer. New Engl J Med 378(13):1242–1244
doi: 10.1056/NEJMe1800419
pubmed: 29590539
Schmidt HB, Jaafar ZA, Wulff BE, Rodencal JJ, Hong K, Aziz-Zanjani MO, Jackson PK, Leonetti MD, Dixon SJ, Rohatgi R et al (2022) Oxaliplatin disrupts nucleolar function through biophysical disintegration. Cell Rep. 41(6):111629. https://doi.org/10.1016/j.celrep.2022.111629
doi: 10.1016/j.celrep.2022.111629
pubmed: 36351392
Schulten HJ, Bakhashab S (2019) Meta-analysis of microarray expression studies on metformin in cancer cell lines. Int J Mol Sci 20(13):1–15. https://doi.org/10.3390/ijms20133173
doi: 10.3390/ijms20133173
Sheth SS, Bodnar JS, Ghazalpour A, Thipphavong CK, Tsutsumi S, Tward AD, Demant P, Kodama T, Aburatani H, Lusis AJ (2006) Hepatocellular carcinoma in txnip-deficient mice. Oncogene 25(25):3528–3536
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A (2017) Colorectal cancer statistics, 2017. CA A Cancer J Clin 67(3):177–193
Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA A Cancer J Clin 70(1):7–30
Stoltzman CA, Peterson CW, Breen KT, Muoio DM, Billin AN, Ayer DE (2008) Glucose sensing by MondoA:Mlx complexes: a role for hexokinases and direct regulation of thioredoxin-interacting protein expression. Proc Natl Acad Sci USA 105(19):6912–6917. https://doi.org/10.1073/PNAS.0712199105
doi: 10.1073/PNAS.0712199105
pubmed: 18458340
pmcid: 2383952
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin 71(3):209–249. https://doi.org/10.3322/CAAC.21660
doi: 10.3322/CAAC.21660
Takahashi Y, Masuda H, Ishii Y, Nishida Y, Kobayashi M, Asai S (2007) Decreased expression of thioredoxin interacting protein mRNA in inflamed colonic mucosa in patients with ulcerative colitis. Oncol Rep 18(3):531–535. https://doi.org/10.3892/or.18.3.531
Tsai VWW, Husaini Y, Sainsbury A, Brown DA, Breit SN (2018) The MIC-1/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab 28(3):353–368. https://doi.org/10.1016/J.CMET.2018.07.018
doi: 10.1016/J.CMET.2018.07.018
pubmed: 30184485
Vicencio JM, Evans R, Green R, An Z, Deng J, Treacy C, Mustapha R, Monypenny J, Costoya C, Lawler K et al (2022) Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans. Cell Death Dis 13(3):274. https://doi.org/10.1038/S41419-022-04701-3
Waldhart AN, Dykstra H, Peck AS, Boguslawski EA, Madaj ZB, Wen J, Veldkamp K, Hollowell M, Zheng B, Cantley LC et al (2017) Phosphorylation of TXNIP by AKT mediates acute influx of glucose in response to insulin. Cell Rep 19(10):2005–2013
doi: 10.1016/j.celrep.2017.05.041
pubmed: 28591573
pmcid: 5603216
Wallin U, Glimelius B, Jirström K, Darmanis S, Nong RY, Pontén F, Johansson C, Påhlman L, Birgisson H (2011a) Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer. Br J Cancer 104(10):1619–1627. https://doi.org/10.1038/bjc.2011.112
doi: 10.1038/bjc.2011.112
pubmed: 21468045
pmcid: 3101900
Wallin U, Glimelius B, Jirström K, Darmanis S, Nong RY, Pontén F, Johansson C, Påhlman L, Birgisson H (2011b) Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer. Br J Cancer 104(10):1619–1627. https://doi.org/10.1038/bjc.2011.112
doi: 10.1038/bjc.2011.112
pubmed: 21468045
pmcid: 3101900
Wang Z, He L, Li W, Xu C, Zhang J, Wang D, Dou K, Zhuang R, Jin B, Zhang W et al (2021) GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma. J Immunother Cancer. https://doi.org/10.1136/JITC-2021-002787
Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, Ward RL, Hawkins NJ, Quinn DI, Russell PJ et al (2003) Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci USA 100(6):3410–3415. https://doi.org/10.1073/PNAS.0530278100
doi: 10.1073/PNAS.0530278100
pubmed: 12624183
pmcid: 152306
Wilde BR, Ye Z, Yeh Lim T, Ayer DE (2019) Cellular acidosis triggers human mondoa transcriptional activity by driving mitochondrial ATP production. eLife 8:e40199. https://doi.org/10.7554/ELIFE.40199
Woolston CM, Madhusudan S, Soomro IN, Lobo DN, Reece-Smith AM, Parsons SL, Martin SG (2013) Thioredoxin interacting protein and its association with clinical outcome in gastro-oesophageal adenocarcinoma. Redox Biol 1(1):285–291. https://doi.org/10.1016/J.REDOX.2013.04.006
doi: 10.1016/J.REDOX.2013.04.006
pubmed: 24024162
pmcid: 3757700
Wu N, Zheng B, Shaywitz A, Dagon Y, Tower C, Bellinger G, Shen CH, Wen J, Asara J, McGraw TE et al (2013) AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. Mol Cell 49(6):1167–1175. https://doi.org/10.1016/J.MOLCEL.2013.01.035
doi: 10.1016/J.MOLCEL.2013.01.035
pubmed: 23453806
pmcid: 3615143
Yang L, Chang CC, Sun Z, Madsen D, Zhu H (2017) GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Nat Med 23:1158–1166. https://www.nature.com/articles/nm.4394
Yang Y, Neo SY, Chen Z, Cui W, Chen Y, Guo M, Wang Y, Xu H, Kurzay A, Alici E et al (2020) Thioredoxin activity confers resistance against oxidative stress in tumor-infiltrating NK cells. J Clin Investig 130(10):5508–5522. https://doi.org/10.1172/JCI137585
doi: 10.1172/JCI137585
pubmed: 32673292
pmcid: 7524507
Yao H, Chen X, Wang T, Kashif M, Qiao X, Tüksammel E, Larsson LG, Okret S, Sayin VI, Qian H et al (2023) A MYC-controlled redox switch protects B lymphoma cells from EGR1-dependent apoptosis. Cell Rep. https://doi.org/10.1016/j.celrep.2023.112961
Yi S, Sun J, Qiu L, Fu W, Wang A, Liu X, Yang Y, Kadin ME, Tu P, Wang Y (2018) Dual role of EZH2 in cutaneous anaplastic large cell lymphoma: promoting tumor cell survival and regulating tumor microenvironment. J Investig Dermatol 138(5):1126–1136
doi: 10.1016/j.jid.2017.10.036
pubmed: 29248547
Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J (2010) Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 11(2):136–140. https://doi.org/10.1038/NI.1831
doi: 10.1038/NI.1831
pubmed: 20023662
Zhou X, Liang T, Deng J, Ng K, Li M, Lv C, Chen J, Yang K, Ma Z, Ma W et al (2021) Differential and prognostic significance of HOXB7 in gliomas. Front Cell Dev Biol. https://doi.org/10.3389/FCELL.2021.697086
Zhou Z, Li W, Song Y, Wang L, Zhang K, Yang J, Zhang W, Su H, Zhang Y (2013) Growth differentiation factor-15 suppresses maturation and function of dendritic cells and inhibits tumor-specific immune response. PLoS ONE 8(11):e78618. https://doi.org/10.1371/JOURNAL.PONE.0078618
Zhu J, Powis De Tenbossche CG, Cané S, Colau D, Van Baren N, Lurquin C, Schmitt-Verhulst AM, Liljeström P, Uyttenhove C, Van Den Eynde BJ (2017) Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes. Nat Commun 8(1):1404. https://doi.org/10.1038/s41467-017-00784-1
Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol. https://doi.org/10.1038/nri2216